| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705166 | Ophthalmology | 2017 | 12 Pages |
Abstract
Current level I evidence suggests that intravitreal pharmacotherapy with anti-VEGF agents is effective and safe for ME secondary to BRVO. Prolonged delay in treatment is associated with less improvement in visual acuity (VA). Level I evidence also indicates that intravitreal corticosteroids are effective and safe for the management of ME associated with BRVO; however, corticosteroids are associated with increased potential ocular side effects (e.g., elevated intraocular pressure, cataracts). Laser photocoagulation remains a safe and effective therapy, but VA results lag behind the results for anti-VEGF therapies.
Keywords
PRNBCVAlogMARCRVOBRVOIAIRVOILMiOpCFTIntravitreal triamcinoloneFDAIVBCPTRBZIntravitreal bevacizumabCStArteriovenousMacular edemaCurrent Procedural TerminologyBranch retinal vein occlusionRetinal vein occlusionCentral retinal vein occlusionOctBRAVObest-corrected visual acuityOptical coherence tomographyGENEVAVisual acuityranibizumabFood and Drug Administrationcentral subfield thicknesscentral foveal thicknesspro re natainternal limiting membraneVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Intraocular pressurelogarithm of the minimum angle of resolutionScoreHORIZON
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Justis P. MD, Stephen J. MD, Steven MD, Jennifer E. MD, PhD, Prithvi MD, MHS, Scott D. MD, Sophie J. MD,